...
首页> 外文期刊>Clinical and vaccine immunology: CVI >T-Cell Response to Human Papillomavirus Type 58 L1, E6, and E7 Peptides in Women with Cleared Infection, Cervical Intraepithelial Neoplasia, or Invasive Cancer
【24h】

T-Cell Response to Human Papillomavirus Type 58 L1, E6, and E7 Peptides in Women with Cleared Infection, Cervical Intraepithelial Neoplasia, or Invasive Cancer

机译:明确感染,宫颈上皮内瘤变或浸润性癌妇女对人乳头瘤病毒58型L1,E6和E7肽的T细胞反应

获取原文
           

摘要

Human papillomavirus type 58 (HPV-58) exists in a relatively high prevalence in certain parts of the world, including East Asia. This study examined the T-cell response to HPV-58 L1, E6, and E7 peptides among women with cleared infection, cervical intraepithelial neoplasia grade 2 (CIN2) or CIN3, or invasive cervical cancer (ICC). Peptides found to be reactive in the in vitro peptide binding assay or mouse-stimulating study were tested with a gamma interferon (IFN-γ) enzyme-linked immunospot (ELISPOT) assay to detect peptide-specific responses from the peripheral blood mononuclear cells (PBMC) collected from 91 HPV-58-infected women (32 with cleared infection, 16 CIN2, 15 CIN3, and 28 ICC). Four HLA-A11-restricted HPV-58 L1 peptides, located at amino acid positions 296 to 304, 327 to 335, 101 to 109, and 469 to 477, showed positive IFN-γ ELISPOT results and were mainly from women with cleared infection. Two HLA-A11-restricted E6 peptides (amino acid positions 64 to 72 and 94 to 102) and three HLA-A11-restricted E7 peptides (amino acid positions 78 to 86, 74 to 82, and 88 to 96) showed a positive response. A response to E6 and E7 peptides was mainly observed from subjects with CIN2 or above. One HLA-A2-restricted E6 peptide, located at amino acid position 99 to 107, elicited a positive response in two CIN2 subjects. One HLA-A24-restricted L1 peptide, located at amino acid position 468 to 476, also elicited a positive response in two CIN2 subjects. In summary, this study has identified a few immunogenic epitopes for HPV-58 E6 and E7 proteins. It is worthwhile to further investigate whether responses to these epitopes have a role in clearing an established cervical lesion.
机译:人类乳头瘤病毒58型(HPV-58)在世界上某些地区(包括东亚)的流行率较高。这项研究检查了感染明确,宫颈上皮内瘤样变2级(CIN2)或CIN3或浸润性宫颈癌(ICC)的女性对HPV-58 L1,E6和E7肽的T细胞反应。在体外肽结合试验或小鼠刺激研究中发现有反应性的肽用γ-干扰素(IFN-γ)酶联免疫斑点法(ELISPOT)测定,以检测来自从91例被HPV-58感染的妇女(32例已清除感染,16例CIN2、15例CIN3和28例ICC)收集的外周血单个核细胞(PBMC)。位于氨基酸位置296至304、327至335、101至109和469至477的4种HLA-A11限制性HPV-58 L1肽显示出IFN-γELISPOT阳性结果,并且主要来自感染明确的女性。两个HLA-A11限制性E6肽(氨基酸位置64至72和94至102)和三个HLA-A11限制性E7肽(氨基酸位置78至86、74至82和88至96)显示阳性反应。主要从具有CIN2或更高水平的受试者中观察到对E6和E7肽的反应。一个HLA-A2限制性E6肽位于99-107位氨基酸,在两名CIN2受试者中引起了阳性反应。位于氨基酸位置468至476的一种HLA-A24限制性L1肽也引起了两名CIN2受试者的阳性反应。总而言之,这项研究已经确定了HPV-58 E6和E7蛋白的一些免疫原性表位。值得进一步研究对这些表位的反应是否在清除已建立的宫颈病变中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号